Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the provided transcript. The management did not discuss raising capital via debt or equity during the call. They highlighted ongoing investments in CAPEX (~Rs. 100 crore for FY18 and similar for FY19) funded through operational means. The focus remains on progressing clinical trials and business growth without reference to external fundraising. Any future financing needs were not addressed or indicated in this transcript.

Any current/future capex/capital investment/strategic investment?

Suven Life Sciences is constructing an additional block to accommodate new requirements for high potency compounds. The planned capital expenditure (CAPEX) for this expansion is approximately Rs. 120 crore. As of the date of the call, around Rs. 25-30 crore has already been spent with orders placed and equipment arriving. The bulk of this CAPEX will be incurred over the next two quarters, with some spillover into the next financial year. Total CAPEX for FY18 is expected to be around Rs. 90-100 crore. For FY19, a similar range of CAPEX is anticipated, including maintenance and spillover costs o

Future growth expectations in sales/revenue/volumes?

Suven Life Sciences expects overall topline growth of 5% to 10% for the next 6 months and potentially beyond. CRAMS (Contract Research and Manufacturing Services) business is expected to grow by around 10%, compensating for the decline in Specialty Chemicals. Specialty Chemicals segment is anticipated to see a 20%-25% de-growth for FY18 due to generic competition, stabilizing post this decline. Repeat business (commercial launches) guidance is around Rs. 70 crore for FY18, with a possibility of increase by Rs. 10-15 crore. Patient enrollment for Phase-2 clinical trials is progressing, with com

Future growth expectations in earnings/operating earnings/profits/EPS?

Suven Life Sciences expects overall topline growth of 5% to 10% in the next 6 months. Bottom-line (profit) growth is guided at up to 20% over the same period. EBITDA margins are expected around 35% for FY18. Core CRAMS segment EBITDA margins projected above 30%, potentially around 39% for the half year. Specialty Chemicals segment is expected to decline by 20-25% in FY18 due to generic competition but will stabilize thereafter. Repeat orders (commercial launches) are projected around Rs. 70 crore for FY18, with potential to increase slightly. The company anticipates improved product mix and in

Current/ Expected Orderbook/ Pending Orders?

Current orderbook details are not explicitly specified in the transcript. Pending orders: Mentioned a pending order of about Rs. 30 crore related to commercial launches (Page 8). Repeat orders for FY18 expected around Rs. 70 crore, with a possibility to increase by Rs. 10-15 crore (Page 5). CRAMS revenue for the quarter is Rs. 91.7 crore, including Rs. 16 crore from repeat orders (Page 10, 7). Specialty Chemicals de-growth expected at 20-25% for the full year, leading to lower orders in this segment (Page 2, 7). The company anticipates 5%-10% topline growth overall in FY18, indicatin

Suven Life Sciences LtdQ2 FY18Healthcare Services

Suven Life Sciences Ltd Q2 FY18 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹308Market Cap: ₹9.5K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

Suven Life Sciences expects overall topline growth of 5% to 10% for the next 6 months and potentially beyond.
CRAMS (Contract Research and Manufacturing Services) business is expected to grow by around 10%, compensating for the decline in Specialty Chemicals.
Specialty Chemicals segment is anticipated to see a 20%-25% de-growth for FY18 due to generic competition, stabilizing post this decline.
Repeat business (commercial launches) guidance is around Rs. 70 crore for FY18, with a possibility of increase by Rs. 10-15 crore.
Patient enrollment for Phase-2 clinical trials is progressing, with completion expected by late 2018 and data results by mid-2019, which may impact future growth.
Incremental growth also anticipated from preclinical compounds moving to Phase-1 clinical trials and planned Phase-2 trials for new molecules starting next year.

Margin guidance

Category 3

Suven Life Sciences expects overall topline growth of 5% to 10% in the next 6 months.
Bottom-line (profit) growth is guided at up to 20% over the same period.
EBITDA margins are expected around 35% for FY18.
Core CRAMS segment EBITDA margins projected above 30%, potentially around 39% for the half year.
Specialty Chemicals segment is expected to decline by 20-25% in FY18 due to generic competition but will stabilize thereafter.
Repeat orders (commercial launches) are projected around Rs. 70 crore for FY18, with potential to increase slightly.
The company anticipates improved product mix and increased repeat orders to drive margins and profitability.
R&D spend expected to remain steady around Rs. 60 crore annually.
CAPEX guidance is approximately Rs. 90-100 crore for FY18, with similar levels expected next year.

See what Suven Life Sciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
The management did not discuss raising capital via debt or equity during the call.
They highlighted ongoing investments in CAPEX (~Rs. 100 crore for FY18 and similar for FY19) funded through operational means.
The focus remains on progressing clinical trials and business growth without reference to external fundraising.
Any future financing needs were not addressed or indicated in this transcript.

Order book

Current orderbook details are not explicitly specified in the transcript.
Pending orders: Mentioned a pending order of about Rs. 30 crore related to commercial launches (Page 8).
Repeat orders for FY18 expected around Rs. 70 crore, with a possibility to increase by Rs. 10-15 crore (Page 5).
CRAMS revenue for the quarter is Rs. 91.7 crore, including Rs. 16 crore from repeat orders (Page 10, 7).
Specialty Chemicals de-growth expected at 20-25% for the full year, leading to lower orders in this segment (Page 2, 7).
The company anticipates 5%-10% topline growth overall in FY18, indicating some new orders or ramp-ups compensating for declines (Page 11).

See what Suven Life Sciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Suven Life Sciences is constructing an additional block to accommodate new requirements for high potency compounds.
The planned capital expenditure (CAPEX) for this expansion is approximately Rs. 120 crore.
As of the date of the call, around Rs. 25-30 crore has already been spent with orders placed and equipment arriving.
The bulk of this CAPEX will be incurred over the next two quarters, with some spillover into the next financial year.
Total CAPEX for FY18 is expected to be around Rs. 90-100 crore.
For FY19, a similar range of CAPEX is anticipated, including maintenance and spillover costs of Rs. 20-30 crore.
No other specific strategic investments were mentioned in this transcript.

Track Suven Life Sciences Ltd — get its next earnings analysis in your feed

How does Suven Life Sciences Ltd rank vs peers in Healthcare Services?

Pro feature

ThisSuven Life Sciences Ltd

Rev 4Mar 3

See where Suven Life Sciences Ltd sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Suven Life Sciences Ltd rank in Healthcare Services?

Compare Suven Life Sciences Ltd against every Healthcare Services company (Q2 FY18) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Suven Life Sciences Ltd's management said in earlier quarters

Others in Healthcare Services this season

KMC Speciality Hospitals (India) Ltd (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
KMC Speciality Hospitals (India) Ltd (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
Vimta Labs Ltd (Q3 FY25)
Q3 FY25 Revenue from Operations: ₹899 Mn . Key concall takeaways from Vimta Labs Ltd's Q3 FY25 earnings call — and how it ranks against sector peers.
3B Blackbio DX Ltd (Q4 FY24)
41% increase). Key concall takeaways from 3B Blackbio DX Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →